New drug combo aims to fight untreatable liver cancer
NCT ID NCT05557838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how well the drugs control the cancer. The goal is to see if this drug pair can offer a better option for patients who have not had prior systemic therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immunotherapy drugs given by IV infusion)
What this could lead to
If successful, this combination could become a new first-line treatment option for Chinese patients with advanced liver cancer, potentially improving survival and tumor control.
What could go wrong
This is an open-label, single-country study with no placebo group, so results may be less definitive. Immunotherapy can cause serious immune-related side effects, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100021, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 211405, China
-
Research Site
Beijing, CN-100730, China
-
Research Site
Changsha, 410005, China
-
Research Site
Changsha, 410013, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Fuzhou, 350011, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Guangzhou, 510260, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150081, China
-
Research Site
Jinan, 2501117, China
-
Research Site
Nanjing, 2100008, China
-
Research Site
Nanjing, 210009, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Tianjin, 300000, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430079, China
-
Research Site
Xi'an, 710038, China
-
Research Site
Zhangjiagang, 215699, China
-
Research Site
Zhengzhou, 450008, China